Welcome to our dedicated page for MIRA Pharmaceuticals news (Ticker: MIRA), a resource for investors and traders seeking the latest updates and insights on MIRA Pharmaceuticals stock.
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a pre-clinical-stage pharmaceutical development company renowned for its innovative approach to treating neurologic and neuropsychiatric disorders. The company is currently focused on two groundbreaking neuroscience programs: the novel oral pharmaceutical marijuana analog, MIRA-55, and the patent-pending oral ketamine analog, Ketamir-2.
MIRA-55 is under investigation as a potential treatment for anxiety and cognitive decline, particularly linked to early-stage dementia. Unlike traditional THC, which can impair cognitive function, MIRA-55 has shown potential to improve memory significantly without the adverse effects. Recently, the U.S. Drug Enforcement Administration (DEA) concluded that MIRA-55 is not a controlled substance, paving the way for more focused development efforts in the $90 billion neurological and $30 billion cannabis markets.
Ketamir-2 is a novel compound designed to deliver ultra-rapid antidepressant effects, providing hope for those battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI), and post-traumatic stress disorder (PTSD). The DEA has also determined that Ketamir-2 is not a controlled substance, which enhances its development potential. Recent collaborations with Pharmaseed Ltd. and Frontage Laboratories have yielded promising preclinical results, demonstrating Ketamir-2’s efficacy in treating TRD, PTSD, and neuropathic pain. The company aims to submit an Investigational New Drug (IND) Application to the FDA by the end of the year, a significant step toward human clinical trials.
MIRA Pharmaceuticals has partnered with renowned entities such as InSilicoTrials, Pharmaseed Ltd., and Memorial Sloan Kettering Cancer Center to leverage AI and computational simulations in drug development. These strategic collaborations have accelerated the development process, providing robust data on the safety and efficacy of MIRA’s drug candidates.
Under the leadership of CEO Erez Aminov and the newly appointed Chief Scientific Advisor, Dr. Itzchak Angel, the company continues to push the boundaries of neuropharmacology. Dr. Angel brings over 40 years of experience in drug development, having played pivotal roles in advancing several drugs through to clinical trials.
Financial and Market Potential: MIRA Pharmaceuticals represents a significant commercial opportunity in the multi-billion dollar market for neuropharmacological therapies. With a strong pipeline and strategic collaborations, the company is well-positioned to meet the unmet needs of millions suffering from neuropsychiatric disorders.
For more information about their ongoing projects and financial reports, visit www.mirapharmaceuticals.com.
FAQ
What is the current stock price of MIRA Pharmaceuticals (MIRA)?
What is the market cap of MIRA Pharmaceuticals (MIRA)?
What is MIRA Pharmaceuticals, Inc.?
What are MIRA Pharmaceuticals' main products?
What recent achievements has MIRA Pharmaceuticals made?
Who are MIRA Pharmaceuticals' key partners?
Who leads MIRA Pharmaceuticals?
What is the market potential for MIRA Pharmaceuticals?
What makes MIRA-55 different from traditional THC?
What are the benefits of Ketamir-2 compared to traditional ketamine?
What are the future plans for MIRA Pharmaceuticals?
How does MIRA Pharmaceuticals leverage technology in drug development?
